|
显示项目 534316-534325 / 2348406 (共234841页)
<< < 53427 53428 53429 53430 53431 53432 53433 53434 53435 53436 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2018-09-10T18:07:35Z |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Nash, P. and Kirkham, B. and Okada, M. and Rahman, P. and Combe, B. and Burmester, G.-R. and Adams, D.H. and Kerr, L. and Lee, C. and Shuler, C.L. and Genovese, M. and Ahmed, K. and Alper, J. and Barkham, N. and Bennett, R.E. and Garc\\'ia, F.J.B. and Alonso, R.B. and Blumstein, H.B. and Brooks, M.S. and Burmester, G.-R. and Cagnoli, P. and Caldron, P.H. and Cantagrel, A. and Chen, D.-Y. and Churchill, M.A. and Codding, C.E. and Combe, B. and Deane, P.M.G. and Del Giudice, J. and Deodhar, A.A. and Dhar, R.K. and Dokoupilova, E. and Egan, R.M. and Everding, A. and Gal\\'indez, E. and Genovese, M. and Goddard, D.H. and Gottlieb, A. and Goupille, P. and Griffin, R.M. and Gupta, R.C. and Hall, S. and Hatti, K. and Howell, M.P. and Huang, Y.-H. and Jajoo, R. and Janssen, N.M. and Kiltz, U. and Kivitz, A.J. and Klein, S.J. and Korkosz, M.P. and Kotha, R. and Kremer, J.M. and Lue, C. and de la Fuente, J.L.M. and Marzo-Ortega, H. and Masmitja, J.G. and Mease, P.J. and Meroni, P.L. and Mueller, E.C. and Nandagudi, A.C. and Nash, P. and Fern\\'andez-Nebro, A. and Neuwelt, C.M. and Orbai, A.M. and Oza, M.R. and Parks, D.L. and Pattanaik, D. and Rell-Bakalarska, M.E. and Rosmarin, D. and Roussou, E. and Rychlewska-Hanczewksa, A.I. and Sikes, D.H. and Stack, M.T. and Sunkureddi, P. and Tahir, H. and Tha?i, D. and Tsai, T.-F. and Turkiewicz, A.M. and Unger, L. and Cabello, R.V. and Wagner, U. and Wei, C.-C. and Wells, A.F. and Youssef, P. and Zielinska, A.; TSEN-FANG TSAI |
| 臺大學術典藏 |
2020-10-22T07:27:50Z |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Okada M.; Kirkham B.; Nash P.; Nash P.;Kirkham B.;Okada M.;Rahman P.;Combe B.;Burmester G.-R.;Adams D.H.;Kerr L.;Lee C.;Shuler C.L.;Genovese M.;Ahmed K.;Alper J.;Barkham N.;Bennett R.E.;Garc?A F.J.B.;Alonso R.B.;Blumstein H.B.;Brooks M.S.;Burmester G.-R.;Cagnoli P.;Caldron P.H.;Cantagrel A.;Chen D.-Y.;Churchill M.A.;Jr, Codding C.E.;Combe B.;Deane P.M.G.;Del Giudice J.;Deodhar A.A.;Dhar R.K.;Dokoupilova E.;Egan R.M.;Everding A.;Gal?Ndez E.;Genovese M.;Goddard D.H.;Gottlieb A.;Goupille P.;Griffin R.M.;Gupta R.C.;Hall S.;Hatti K.;Howell M.P.;Huang Y.-H.;Jajoo R.;Janssen N.M.;Kiltz U.;Kivitz A.J.;Klein S.J.;Korkosz M.P.;Kotha R.;Kremer J.M.;Lue C.;De La Fuente J.L.M.;Marzo-Ortega H.;Masmitja J.G.;Mease P.J.;Meroni P.L.;Mueller E.C.;Nandagudi A.C.;Nash P.;Fern?Ndez-Nebro A.;Neuwelt C.M.;Orbai A.M.;Oza M.R.;Parks D.L.;Pattanaik D.;Rell-Bakalarska M.E.;Rosmarin D.;Roussou E.;Rychlewska-Hanczewksa A.I.;Sikes D.H.;Stack M.T.;Sunkureddi P.;Tahir H.;Tha?I D.;Tsen-Fang Tsai;Turkiewicz A.M.;Unger L.;Cabello R.V.;Wagner U.;Wei C.-C.;Wells A.F.;Youssef P.;Zielinska A.; Korkosz M.P.; Klein S.J.; Kiltz U.; Kivitz A.J.; Janssen N.M.; Rahman P.; Combe B.; Burmester G.-R.; Adams D.H.; Kerr L.; Lee C.; Shuler C.L.; Genovese M.; Ahmed K.; Alper J.; Barkham N.; Bennett R.E.; Garc?a F.J.B.; Alonso R.B.; Blumstein H.B.; Brooks M.S.; Burmester G.-R.; Cagnoli P.; Caldron P.H.; Cantagrel A.; Chen D.-Y.; Churchill M.A.; Jr, Codding C.E.; Combe B.; Deane P.M.G.; Del Giudice J.; Deodhar A.A.; Dhar R.K.; Dokoupilova E.; Egan R.M.; Everding A.; Gal?ndez E.; Genovese M.; Goddard D.H.; Gottlieb A.; Goupille P.; Griffin R.M.; Gupta R.C.; Hall S.; Hatti K.; Howell M.P.; Huang Y.-H.; Jajoo R.; Zielinska A.; Wells A.F.; Youssef P.; Kotha R.; Kremer J.M.; Lue C.; de la Fuente J.L.M.; Marzo-Ortega H.; Masmitja J.G.; Mease P.J.; Meroni P.L.; Mueller E.C.; Nandagudi A.C.; Nash P.; Fern?ndez-Nebro A.; Neuwelt C.M.; Orbai A.M.; Oza M.R.; Parks D.L.; Pattanaik D.; Rell-Bakalarska M.E.; Rosmarin D.; Roussou E.; Rychlewska-Hanczewksa A.I.; Sikes D.H.; Stack M.T.; Sunkureddi P.; Tahir H.; Tha?i D.; TSEN-FANG TSAI; Turkiewicz A.M.; Unger L.; Cabello R.V.; Wagner U.; Wei C.-C. |
| 中山醫學大學 |
2021 |
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies
|
Kiltz, U; Wei, JCC; van der Heijde, D; van den Bosch, F; Walsh, JA; Boonen, A; Gensler, LS; Hunter, T; Carlier, H; Dong, Y; Li, XQ; Bolce, R; Strand, V; Braun, J |
| 臺大學術典藏 |
2021-10-28T07:11:15Z |
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
|
Combe B.; TSEN-FANG TSAI; Huffstutter J.E.; Sprabery A.T.; Lin C.-Y.; Park S.Y.; Kronbergs A.; Hufford M.M.; Nash P. |
| 臺北醫學大學 |
2008-02 |
Ixel® / 鬱思樂®膠囊
|
藥劑部 |
| 南台科技大學 |
2002-06 |
IXIA-APTS: 網路設備自動檢測機制之研發與建置
|
張明裕; 李昶清 |
| 中國醫藥大學 |
2012-09 |
Ixora parviflora Protects against UVB-Induced Photoaging by Inhibiting the Expression of MMPs, MAP Kinases, and COX-2 and by Promoting Type I Procollagen Synthesis
|
溫國慶(Kuo-Ching Wen);(Pei-Ching Fan);蔡尚元(Shang-Yuan Tsai);(I-Chen Shih);江秀梅(Hsiu-Mei Chiang)* |
| 中國醫藥大學 |
2014-10-24 |
Ixora parviflora protects against UVB-induced photoaging by inhibiting the expression of MMPs, MAP kinases, and COX-2 and by promoting type I procollagen synthesis
|
溫國慶(Kuo-Ching Wen);范沛晴(Pei-Ching Fan);施宜貞(I-Chen Shih);江秀梅(Hsiu-Mei Chiang)* |
| 中國醫藥大學 |
2010-11 |
Ixorapeptide I and ixorapeptide II, bioactive peptides isolated from Ixora coccinea
|
李家琳(Chia-Lin Lee); (Yung-Chih Lia); (Tsong-Long Hwang); (Chin-Chung Wu); (Fang-Rong Chang)*; 吳永昌* |
| 東海大學 |
2013 |
Ixosin-B amide 之胜?類緣物的設計、合成及抗菌活性
|
廖柏宗; Liao, Po-Tsung |
显示项目 534316-534325 / 2348406 (共234841页)
<< < 53427 53428 53429 53430 53431 53432 53433 53434 53435 53436 > >>
每页显示[10|25|50]项目
|
